Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Diagnosis and Treatment of Pituitary Tumors

Freda, P. U. · 1999 · Journal of Clinical Endocrinology & Metabolism

Abstract

THE DIAGNOSIS and treatment of pituitary tumors has been improved by a number of recent advances. Diagnosis of hormone hypersecretion has been facilitated by the development of more sensitive and reliable assays, especially for ACTH and insulin-like growth factor I (IGF)-I. Pituitary tumors can now be visualized more accurately due to continued improvements in magnetic resonance imaging (MRI) techniques with gadolinium enhancement. Petrosal sinus sampling can be used to measure hormone levels in the venous blood draining the pituitary. This has proved helpful in the differential diagnosis of Cushing’s disease. Treatment of pituitary tumors has been improved by advances in transsphenoidal surgery and radiotherapy and by the development of remarkably effective drugs for PRL and GH-secreting tumors. The primary therapeutic objectives are to normalize levels of hypersecreted hormones and to reduce tumor size to prevent damage to normal pituitary tissue and surrounding parasellar structures, especially the optic chiasm. This short review describes our current approach to the diagnosis and treatment of hormone- and nonhormone-secreting pituitary tumors. PRL is the hormone most frequently secreted in excess by pituitary tumors. Although very high PRL levels (>250 ng/mL) are virtually always indicative of a prolactinoma, other causes of hyperprolactinemia need to be considered with more modest elevations of serum PRL levels (1). Physiological elevations of PRL are seen normally during pregnancy and lactation, as well as during sleep and with stress. A variety of drugs, most notably dopamine receptor antagonists such as the neuroleptics and metoclopramide, often cause hyperprolactinemia. Elevated PRL levels also occur in primary hypothyroidism and in renal failure. In the absence of these conditions, however, hyperprolactinemia usually indicates a hypothalamic or pituitary disorder, but not necessarily a prolactinoma. Any sellar or parasellar process that compresses the pituitary stalk and interferes with tonic dopamine inhibition of PRL secretion can lead to hyperprolactinemia. This is an important consideration therapeutically because the treatment of patients with large pituitary masses and moderately elevated PRL levels is quite different than the treatment of patients with large prolactinomas. GH-secreting tumors may also hypersecrete PRL. PRL levels are usually greater than 250 ng/mL in patients with large prolactinomas and are usually less than 100 ng/mL in patients with pituitary stalk compression. PRL levels may be only moderately elevated (<100 ng/mL) in patients with PRL-secreting microadenomas, defined as less than 10 mm in size. Patients without any obvious cause of hyperprolactinemia and with normal high resolution MRI scans are classified as having idiopathic hyperprolactinemia. Some of these patients may actually have very small prolactinomas, but the etiology of the hyperprolactinemia in many of these patients remains unclear. Patients with PRL-secreting microadenomas usually present with symptoms caused by the high PRL levels. Patients with PRL-secreting macroadenomas, however, often present with additional symptoms related to the presence of a pituitary mass lesion. The treatment of patients with prolactinomas varies with the symptoms of the patient and the size of the tumor (2). Hyperprolactinemia causes hypogonadotropic hypogonadism in women and men, primarily due to the inhibitory effect of high PRL levels on hypothalamic GnRH release. The most common symptoms of hyperprolactinemia are amenorrhea and galactorrhea in women and decreased libido and impotence in men. Treatment is clearly indicated to restore fertility and to reverse symptomatic hypogonadism. The long-term effects of hypogonadism on bone mineral density and the cardiovascular system also need to be considered. A major therapeutic objective is also to reduce the size of the tumor and to limit future growth. Reduction in tumor size is of primary importance in patients with large macroadenomas and symptoms of a mass lesion, including visual symptoms secondary to compression of the optic chiasm, cranial neuropathies, and hypopituitarism. This is not the case with microadenomas. Several studies now support the view that in the majority of patients, untreated microadenomas do not grow into macroadenomas (2, 3). Thus, the presence of a small tumor per se (in the absence of clinical symptoms) is not a definite indication for surgical intervention or for medical intervention. These patients must, however, continue to be carefully monitored. The presence of a macroadenoma, however, even without symptoms, usually warrants treatment to prevent future growth. Medical treatment with long-acting dopamine agonists is very effective in reducing PRL levels and restoring gonadal function in patients with prolactinomas. In addition, these drugs cause significant tumor shrinkage in ∼75% of patients (2, 4). In some patients with large invasive tumors, t

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.84.11.3859

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 158

Metadata

Authors
Freda, P. U.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1999-11-01
Volume
84
Issue
11
Pages
3859-3866
ISSN
0021-972X (ISSN-L)
OpenAlex
W2002764136
Cited by
158
References
3
FWCI
7.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and Treatment of Pituitary Tumors. https://app.cochat.ai/papers/10.1210/jc.84.11.3859
The paper
Freda, P. U. (1999). Diagnosis and Treatment of Pituitary Tumors. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.11.3859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.